Listener feedback on sports “disqualification,” big digoxin news, Brugada syndrome, another positive finerenone study, and unblinded transcatheter trials are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• JACC EP Paper https://www.jacc.org/doi/10.1016/j.jacep.2025.03.013

II Digoxin News

• DIGIT HF Baseline Characteristics paper https://doi.org/10.1002/ejhf.3679
• DIGIT HF Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC6607489/
• Dig trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
• DECISION trial https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3428
• Ziff et al BMJ meta-analysis https://www.bmj.com/content/351/bmj.h4451

III Brugada Syndrome

• Gomes et al https://doi.org/10.1093/europace/euaf091

IV Another Finerenone Substudy Published

• FINEARTS-HF trial substudy, Bhatt, A et al https://doi.org/10.1016/j.cardfail.2025.05.006
• FINEARTS HF Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
• TOPCAT https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
• TOPCAT regional variation Circ paper https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255

V Another Opinion on Unblinded Transcatheter Intervention Trials

• Kaul https://eurointervention.pcronline.com/article/unblinded-trials-of-transcatheter-interventions-with-subjective-endpoints-what-are-the-implications

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Timing of BP Meds – The BedMed RCT

• MAPEC https://doi.org/10.3109/07420528.2010.510230
• Hygia https://doi.org/10.1093/eurheartj/ehz754
• Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501
• TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X
• BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860
• Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z
• Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2
• Timing of Blood Pressure Meds Doesn’t Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm

II Tirzepatide vs Semaglutide

• SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

III Age-specific Troponins

• Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308
• Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967

IV Return to Play for Gene Positive Phenotype Negative athletes

• Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013

V Rapid Titration of GDMT in HF

STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

• JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020
• STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1
• AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474
• EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I The KETO-CTA Study

• JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
• Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009

II Subclinical AF – Anticoagulate or Not?

Anticoagulation in Subclinical AF May Offer Little Benefit

https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31

Treat AFib ‘Diagnosed’ by Smartwatch

https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp

• JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
• NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
• ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
• McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
• Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
• Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
• American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/

III GLP1a for Treatment of Fatty Liver Disease

• ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258

Features

• CABG Still Superior to Stents Despite FAME 3 Endpoint Swap

https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net